<DOC>
	<DOCNO>NCT01924949</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) adults nosocomial genotype 1 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Adults With Nosocomial Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Body mass index ( BMI ) great equal 18 kg/m^2 . HCV RNA great equal 1000 IU/mL screen . Documented acquisition nosocomial genotype 1 HCV infection within 36 month screen visit . Screening laboratory value within predefined threshold . Use two effective contraception method female childbearing potential sexually active male . Healthy accord medical history physical examination exception HCV diagnosis . Unstable cardiac disease include subject active angina pectoris and/or hospitalization cardiac condition within 24 week prior screen . Prior exposure HCV NS5a inhibitor . Pregnant nursing female . Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) . History solid organ transplantation . Current prior history clinical hepatic decompensation . History clinically significant illness medical disorder may interfere subject treatment , assessment , compliance protocol . Known hypersensitivity LDV , SOF , formulation excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>7977</keyword>
	<keyword>5885</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>SOF</keyword>
	<keyword>LDV</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Ledipasvir</keyword>
	<keyword>FDC</keyword>
</DOC>